×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Clinical: LY-3372689 LOTUS Trial - Phase 2 in Progressive Supranuclear
clinical
1,396 words
KG: PSP
2026-03-28
section:clinical-trials
kind:clinical-trial
topic:psp
topic:oga-inhibitor
topic:tauopathy
Contents
LY-3372689 LOTUS Trial - Phase 2 in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (25)
Aquaporin-4 Polarization Rescue
Score: 0.67
Microglial Purinergic Reprogramming
Score: 0.62
Sphingolipid Metabolism Reprogramming
Score: 0.57
Complement C1q Subtype Switching
Score: 0.57
Glial Glycocalyx Remodeling Therapy
Score: 0.54
Ephrin-B2/EphB4 Axis Manipulation
Score: 0.53
Netrin-1 Gradient Restoration
Score: 0.45
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.78
Competitive APOE4 Domain Stabilization Peptides
Score: 0.75
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.73
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.71
Phase-Separated Organelle Targeting
Score: 0.69
APOE Isoform Expression Across Glial Subtypes
Score: 0.67
Stress Granule Phase Separation Modulators
Score: 0.65
Noradrenergic-Tau Propagation Blockade
Score: 0.64
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.64
Lysosomal Enzyme Trafficking Correction
Score: 0.64
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.63
Lysosomal Calcium Channel Modulation Therapy
Score: 0.63
Lysosomal Membrane Repair Enhancement
Score: 0.60
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.57
Synaptic Vesicle Tau Capture Inhibition
Score: 0.53
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.52
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.51
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.51
Show 20 more
Related Analyses (6)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 1 more
Related Experiments (26)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Show 21 more
See Also (11)
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: activates
Packard Center for ALS Research
institution · KG edge: expressed_in
Dementia Australia
institution · KG edge: associated_with
Alzheimer Indonesia
institution · KG edge: associated_with
DUSP10 Gene
gene · KG edge: associated_with
cdkn2a
gene · KG edge: associated_with
Genes
index · KG edge: activates
Autophagy Enhancement Drug Screening for Neurodegenerat
experiment · KG edge: therapeutic_target
Apoptosis in Neurodegeneration
entity · KG edge: associated_with
Frontotemporal Dementia (FTD)
disease · KG edge: associated_with
Amyotrophic Lateral Sclerosis
redirect · KG edge: expressed_in
Show 6 more
Knowledge Graph (12 edges)
PSP
downregulates
SV2A
PSP
co_discussed
TAU
PSP
co_discussed
T CELL
PSP
co_discussed
SYNAPSE
PSP
co_discussed
STING
PSP
co_discussed
TBI
PSP
co_discussed
VCP
PSP
co_discussed
SLEEP
PSP
co_discussed
SMPD1
PSP
co_discussed
SQSTM1